Addex Therapeutics Ltd (ADXN.SW)
CHF 0.06
(-8.5%)
CHF 0.06
(-8.5%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -10.55 Million CHF | 49.9% |
| 2022 | -21.06 Million CHF | -36.68% |
| 2021 | -15.41 Million CHF | -19.24% |
| 2020 | -12.92 Million CHF | 13.29% |
| 2019 | -14.9 Million CHF | -806.44% |
| 2018 | -1.64 Million CHF | 49.86% |
| 2017 | -3.28 Million CHF | -4.16% |
| 2016 | -3.14 Million CHF | 25.09% |
| 2015 | -4.2 Million CHF | -136.88% |
| 2014 | -1.77 Million CHF | 87.73% |
| 2013 | -14.46 Million CHF | 46.47% |
| 2012 | -27.01 Million CHF | 13.24% |
| 2011 | -31.14 Million CHF | 7.44% |
| 2010 | -33.64 Million CHF | 21.19% |
| 2009 | -42.69 Million CHF | -93.47% |
| 2008 | -22.06 Million CHF | 37.11% |
| 2007 | -35.08 Million CHF | -70.78% |
| 2006 | -20.54 Million CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.08 Million CHF | -8.06% |
| 2024 Q2 | 12.87 Million CHF | 517.17% |
| 2023 FY | -10.55 Million CHF | 49.9% |
| 2023 Q4 | -2.85 Million CHF | -9.16% |
| 2023 Q3 | -2.61 Million CHF | 2.17% |
| 2023 Q2 | -2.67 Million CHF | -9.96% |
| 2023 Q1 | -2.43 Million CHF | 36.35% |
| 2022 Q1 | -5.88 Million CHF | -33.02% |
| 2022 Q3 | -4.04 Million CHF | 44.92% |
| 2022 FY | -21.06 Million CHF | -36.68% |
| 2022 Q2 | -7.35 Million CHF | -24.9% |
| 2022 Q4 | -3.82 Million CHF | 5.58% |
| 2021 Q1 | -2.63 Million CHF | -24.22% |
| 2021 FY | -15.41 Million CHF | -19.24% |
| 2021 Q2 | -4.69 Million CHF | -77.68% |
| 2021 Q3 | -3.59 Million CHF | 23.28% |
| 2021 Q4 | -4.42 Million CHF | -22.95% |
| 2020 FY | -12.92 Million CHF | 13.29% |
| 2020 Q4 | -2.12 Million CHF | 35.86% |
| 2020 Q3 | -3.31 Million CHF | -6.37% |
| 2020 Q2 | -3.11 Million CHF | 27.66% |
| 2020 Q1 | -4.3 Million CHF | -17.82% |
| 2019 Q3 | -3.58 Million CHF | 20.33% |
| 2019 Q1 | -3.04 Million CHF | -52.08% |
| 2019 FY | -14.9 Million CHF | -806.44% |
| 2019 Q4 | -3.65 Million CHF | -1.94% |
| 2019 Q2 | -4.49 Million CHF | -47.98% |
| 2018 FY | -1.64 Million CHF | 49.86% |
| 2018 Q3 | -1.99 Million CHF | -269.86% |
| 2018 Q2 | 1.17 Million CHF | -0.0% |
| 2018 Q1 | 1.17 Million CHF | 257.66% |
| 2018 Q4 | -1.99 Million CHF | 0.0% |
| 2017 Q3 | -746.61 Thousand CHF | 16.45% |
| 2017 FY | -3.28 Million CHF | -4.16% |
| 2017 Q4 | -746.61 Thousand CHF | 0.0% |
| 2017 Q2 | -893.58 Thousand CHF | 0.0% |
| 2017 Q1 | -893.58 Thousand CHF | -7.37% |
| 2016 Q1 | -742.45 Thousand CHF | -8.32% |
| 2016 FY | -3.14 Million CHF | 25.09% |
| 2016 Q4 | -832.23 Thousand CHF | 0.0% |
| 2016 Q3 | -832.23 Thousand CHF | -12.09% |
| 2016 Q2 | -742.45 Thousand CHF | 0.0% |
| 2015 Q4 | -685.41 Thousand CHF | 0.0% |
| 2015 Q2 | -1.41 Million CHF | 0.0% |
| 2015 Q1 | -1.41 Million CHF | -252.17% |
| 2015 FY | -4.2 Million CHF | -136.88% |
| 2015 Q3 | -685.41 Thousand CHF | 51.62% |
| 2014 Q1 | -485.15 Thousand CHF | -84.86% |
| 2014 Q4 | -402.27 Thousand CHF | 0.0% |
| 2014 Q3 | -402.27 Thousand CHF | 17.08% |
| 2014 Q2 | -485.15 Thousand CHF | 0.0% |
| 2014 FY | -1.77 Million CHF | 87.73% |
| 2013 Q3 | -262.44 Thousand CHF | 96.23% |
| 2013 Q4 | -262.44 Thousand CHF | 0.0% |
| 2013 FY | -14.46 Million CHF | 46.47% |
| 2013 Q1 | -6.96 Million CHF | -18.91% |
| 2013 Q2 | -6.96 Million CHF | 0.0% |
| 2012 Q3 | -5.86 Million CHF | 0.0% |
| 2012 FY | -27.01 Million CHF | 13.24% |
| 2012 Q4 | -5.86 Million CHF | 0.0% |
| 2011 FY | -31.14 Million CHF | 7.44% |
| 2010 FY | -33.64 Million CHF | 21.19% |
| 2009 FY | -42.69 Million CHF | -93.47% |
| 2008 FY | -22.06 Million CHF | 37.11% |
| 2007 FY | -35.08 Million CHF | -70.78% |
| 2006 FY | -20.54 Million CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| BB Biotech AG | -206.6 Million CHF | 94.891% |
| Basilea Pharmaceutica AG | 10.45 Million CHF | 201.007% |
| Evolva Holding SA | -105.22 Million CHF | 89.968% |
| Idorsia Ltd | -297.92 Million CHF | 96.457% |
| Kuros Biosciences AG | -13.72 Million CHF | 23.099% |
| Molecular Partners AG | -61.98 Million CHF | 82.969% |
| Relief Therapeutics Holding AG | -98.18 Million CHF | 89.248% |
| Santhera Pharmaceuticals Holding AG | 54.78 Million CHF | 119.27% |